Savara Inc Proceeds from Sale and Collection of Notes Receivable
Savara Inc (SVRA) reported Proceeds from Sale and Collection of Notes Receivable of $405.99 thousand for the 214-month period ending 2014-03-31, per its 10-Q filed 2014-05-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndCollectionOfNotesReceivable · last filed 2014-05-05
- 2014-03-31: .
- 2013-12-31: .
- 2013-09-30: .
- 2013-06-30: .
| Period end | Proceeds from Sale and Collection of Notes Receivable 181 month | Proceeds from Sale and Collection of Notes Receivable 184 month | Proceeds from Sale and Collection of Notes Receivable 187 month | Proceeds from Sale and Collection of Notes Receivable 190 month | Proceeds from Sale and Collection of Notes Receivable 193 month | Proceeds from Sale and Collection of Notes Receivable 196 month | Proceeds from Sale and Collection of Notes Receivable 199 month | Proceeds from Sale and Collection of Notes Receivable 202 month | Proceeds from Sale and Collection of Notes Receivable 205 month | Proceeds from Sale and Collection of Notes Receivable 208 month | Proceeds from Sale and Collection of Notes Receivable 211 month | Proceeds from Sale and Collection of Notes Receivable 214 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $405.99K 10-Q · filed 2014-05-05 | |||||||||||
| 2013-12-31 | $405.99K 10-K · filed 2014-03-26 | |||||||||||
| 2013-09-30 | $405.99K 10-Q · filed 2013-11-04 | |||||||||||
| 2013-06-30 | $405.99K 10-Q · filed 2013-08-05 | |||||||||||
| 2013-03-31 | $405.99K 10-Q · filed 2013-05-15 | |||||||||||
| 2012-12-31 | $405.99K 10-K · filed 2013-03-19 | |||||||||||
| 2012-09-30 | $405.99K 10-Q · filed 2012-11-05 | |||||||||||
| 2012-06-30 | $405.99K 10-Q · filed 2012-08-06 | |||||||||||
| 2012-03-31 | $405.99K 10-Q · filed 2012-05-07 | |||||||||||
| 2011-12-31 | $405.99K 10-K · filed 2012-03-08 | |||||||||||
| 2011-09-30 | $405.99K 10-Q · filed 2011-11-08 | |||||||||||
| 2011-06-30 | $405.99K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |